2/6/2024-Unusual Options Activity In WAL
$WAL-Bearish flow noted in Western Alliance (57.38 -1.66) with 12,797 puts trading, or 4x expected. The Put/Call Ratio is 3.63, while ATM IV is up over 8 points on the day. Earnings are expected on 04/16.
Similar Posts
7/24/2024-Unusual Options Activity In ASTS
AST SpaceMobile is a publicly traded satellite designer and manufacturer based in Midland, Texas, United States.
10/23/2024 -Unusual Options Activity In Spirit Airlines (SAVE)
Spirit Airlines, Inc., stylized as spirit, is a major American ultra-low cost airline headquartered in Dania Beach, Florida, in the Miami metropolitan area.
10/25/2024 -Unusual Options In Expeng (XPEV)
XPeng is a Chinese electric vehicle (EV) company that designs, manufactures, and sells smart EVs
Unusual Options Activity In Western Digital (WDC)
10029 $WDC JUN 20th 2025 50.00 CALLS BOUGHT@ 2.4 vs Open Interest of 263 for a total of $2406960 on the BULL side
8/29/2024- Unusual Options Activity In Eos Energy Enterprises, Inc. (EOSE)
Eos Energy Enterprises, Inc. provides energy storage solutions. The Company manufactures clean energy storage equipment for utility, industrial, and commercial customers. Eos Energy Enterprises operates worldwide.
2/16/2023-Unusual Options Activity In TGTX
TG Therapeutics, Inc., a commercial stage biopharmaceutical company, focuses on the acquisition, development, and commercialization of novel treatments for B-cell diseases. It provides BRIUMVI, an anti-CD20 monoclonal antibody for the treatment of adult patients with relapsing forms of multiple sclerosis (RMS), including clinically isolated syndrome, relapsing-remitting disease, and active secondary progressive disease in adults. The company’s development pipeline comprises Umbralisib, an oral inhibitor of PI3K-delta inhibitor for the treatment of CLL, marginal zone lymphoma, and follicular lymphoma; TG-1701 is an orally available and covalently-bound Bruton’s tyrosine kinase (BTK) inhibitor that exhibits selectivity to BTK in vitro kinase screening; and TG-1801, a bispecific CD47 and CD19 antibody.
